Fulcrum Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2020 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Fulcrum Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2020 to Q2 2024.
  • Fulcrum Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 8.73 %, a 16.6% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 8.73 -1.74 -16.6% Jun 30, 2024
Q1 2024 9.17 -3.77 -29.1% Mar 31, 2024
Q4 2023 9.01 -6.53 -42% Dec 31, 2023
Q3 2023 9.84 -4.91 -33.3% Sep 30, 2023
Q2 2023 10.5 -3.91 -27.2% Jun 30, 2023
Q1 2023 12.9 -1.41 -9.83% Mar 31, 2023
Q4 2022 15.5 +0.25 +1.64% Dec 31, 2022
Q3 2022 14.7 -5.64 -27.7% Sep 30, 2022
Q2 2022 14.4 -14.6 -50.4% Jun 30, 2022
Q1 2022 14.4 -13 -47.5% Mar 31, 2022
Q4 2021 15.3 -14.9 -49.3% Dec 31, 2021
Q3 2021 20.4 -7.54 -27% Sep 30, 2021
Q2 2021 29 +7.01 +31.9% Jun 30, 2021
Q1 2021 27.4 -21.9 -44.5% Mar 31, 2021
Q4 2020 30.2 Dec 31, 2020
Q3 2020 27.9 Sep 30, 2020
Q2 2020 22 Jun 30, 2020
Q1 2020 49.3 Mar 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.